UBS Group’s Liminatus Pharma Warrants LIMNW Stock Holding History

UBS Group’s Portfolio LIMNW Stock Details LIMNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$233	Sell	4,162 -345	-8%	-$19	﹤0.01%	10739
2026 Q2	$338	Hold	4,507	–	–	﹤0.01%	9913
2026 Q1	$180	Buy	4,507 +295	+7%	+$19	﹤0.01%	10048
2025 Q4	$147	Buy	4,212 +3,922	+1,352%	+$396	﹤0.01%	10146
2025 Q3	$43	Sell	290 -1,730	-86%	-$338	﹤0.01%	10041
2025 Q2	$485	Buy	+2,020	New	+$397	﹤0.01%	9814

Other funds holding LIMNW

MMCAP International Grand Cayman, Cayman Islands $1.52B AUM 24.83% 1-Year Est. Return

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $990M AUM 4.73% 1-Year Est. Return

Arena Capital Advisors Los Angeles, California $200M AUM 6.35% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Flow Traders U.S. New York $4.12B AUM 34.04% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $14.9B AUM 3.61% 1-Year Est. Return

DCM

Dupont Capital Management Wilmington, Delaware $14.8M AUM 14.32% 1-Year Est. Return

UBS Group's LIMNW Position: Q3 2026 in Review

UBS Group reduced its Liminatus Pharma Warrants (LIMNW) stake by 7.7% in Q3 2026, selling an estimated $19 and leaving 4,162 shares worth $233. The position accounts for ﹤0.01% of the portfolio, ranked #10739.

UBS Group first reported a position in LIMNW in Q2 2025 and has held it in 6 quarters since. The position peaked at $485 in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMNW as of Q3 2026.

UBS Group held 4,162 shares of Liminatus Pharma Warrants worth $233 as of Q3 2026.
UBS Group sold 345 Liminatus Pharma Warrants shares in Q3 2026, an estimated $19.
Liminatus Pharma Warrants made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10739 holding.
UBS Group first reported a position in Liminatus Pharma Warrants in Q2 2025 and has held it in 6 quarters since.
UBS Group's Liminatus Pharma Warrants position peaked at $485 in Q2 2025.
9 funds tracked by Wall St. Rank held Liminatus Pharma Warrants as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.